Article title: Combinatorial therapeutic approach for treatment of oral squamous cell carcinoma
Authors: Bharadwaj R., Sahu B.P., Haloi J., Laloo D., Barooah P., Keppen C., Deka M. and Medhi S.
Journal: Artificial Cells, Nanomedicine, and Biotechnology
Bibliometrics: Volume 47, Number 01, pages 571–584
DOI: https://doi.org/10.1080/21691401.2019.1573176
When this article was first published online there were some errors in the content which have now been corrected. The affected sections of text that have now been revised are as follows:
Page 574: After the induction period, representative mice from each group were confirmed for the formation of oral squamous cell carcinoma and then the treatment were initiated for a period of 4 weeks. The efficacy of the treatment was checked in the respective group during the treatment phase by sacrificing a representative number of mice at a period of 2 weeks and 4 weeks by comparing them with the normal control group.
Page 576: After the induction period of 16 weeks, representative mice from each group were confirmed for the formation of OSCC both visually and histologically as shown in Figure-5. Afterwards, the mice were subjected for treatment of OSCC with the developed formulations for a period of 4 weeks.
Page 583: The research study conducted on the mice model induced with oral squamous cell carcinoma is to investigate a combination therapy of drugs.
Page 583: The in-vitro results depicted the efficacy of the formed nanoparticles in the treatment of oral squamous cell carcinoma. Considering the H & E staining procedure as the standard diagnostic tool for detection of oral squamous cell carcinoma, we have performed the in-vivo efficacy assay of the developed formulation, which results clearly revealed the efficacy of PTX loaded SLN in combination with AA loaded SLN is quite efficient enough in the treatment of oral cancer. The result outcome of the in-vivo study clearly depicts efficacy of Paclitaxel and Ascorbic acid (1:1) combination in the treatment of the oral squamous cell carcinoma.